Reported 7 months ago
Novo Nordisk CEO Lars Jorgensen has agreed to voluntarily testify in a U.S. Senate hearing focusing on the high prices of weight loss drugs Ozempic and Wegovy. A Senate health panel vote scheduled for June 18 to subpoena Novo has been canceled as Jorgensen will testify in early September. The hearing aims to address why Americans are charged significantly more for these drugs compared to other countries, with Wegovy priced at $1,349/month in the U.S. but significantly lower in Germany and the UK.
Source: YAHOO